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OBJECTIVE: To compare the efficacy of transconjunctival needling revision with 5-fluorouracil versus medical
treatment in glaucomatous eyes with uncontrolled intraocular pressure due to encapsulated bleb after
trabeculectomy.
METHODS: Prospective, randomized, interventional study. A total of 40 eyes in 39 patients with elevated
intraocular pressure and encapsulated blebs diagnosed at a maximum five months after primary
trabeculectomy with mitomycin C were included. The eyes were randomized to either transconjunctival
needling revision with 5- fluorouracil or medical treatment (hypotensive eyedrops). A maximum of two
transconjunctival needling revisions per patient was allowed in the needling arm. All patients underwent
follow-up for 12 months. Successful treatment was defined as an intraocular pressure # 18 mmHg and a 20%
reduction from baseline at the final follow-up. Clinicaltrial.gov: NCT01887223.
RESULTS: Mean intraocular pressure at the final 12-month follow-up was lower in the transconjunctival
needling revision group compared to the medical treatment group. Similar numbers of eyes reached the criteria
for treatment success in both the transconjunctival needling revision group and the medical treatment group.
CONCLUSIONS: Despite similar success rates in eyes randomized to transconjunctival needling revision with 5-
fluorouracil compared to eyes receiving medical treatment, there was a significantly lower mean intraocular
pressure at 12 months after transconjunctival needling revision.
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& INTRODUCTION
To avoid the initiation or progression of visual field
defects, the reduction of intraocular pressure (IOP) is the
aim of treatment for all glaucoma patients. Surgical
treatment is the next step after initial medical treatment
(MT) failure. Trabeculectomy is still the gold standard
surgery for many specialists (1-5), and proper post-
operative management is essential for the achievement of
success during the follow-up period. The identification and
prompt management of the early aspects of bleb failure are
paramount for reducing the rate of ultimate failure of the
filtering procedure (6).
Scarring under or over the scleral flap in the subconjunc-
tival space appears to be the most common event leading to
filtering failure (7,8). Scar tissue formation over the scleral
flap in the subconjunctival space or encapsulated bleb
(Tenon’s capsule cyst) formation may occur at any point
after the initial surgery. Some authors have suggested
encapsulation rates ranging from 13.7% to 29% after
trabeculectomy (9-11). Transconjunctival needling revision
(TNR), which removes part of the fibroses with a minimally
invasive technique and restores filtration, is one treatment
option (6,12). The use of antifibrotic agents, such as 5-
fluorouracil (5-FU) (1,5,6,12) or mitomycin C (MMC) (5), as
adjunctives is suggested to increase the procedural success
rate. Conversely, several authors have proposed MT with
topical hypotensive medication as a successful treatment in
patients with encapsulated blebs (13-15).
Several studies (1,5,12,16-18) have reported different
success rates and some mixed criteria regarding successful
target pressure, bleb morphological features, time of
needling procedure, whether single or multiple procedures
were performed and whether antifibrotic agents were used.
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The purpose of this study was to evaluate the short-term
efficacy of early TNR with 5-FU and to compare its
outcomes to MT in eyes with encapsulated blebs and
uncontrolled IOP after trabeculectomy.
& MATERIALS AND METHODS
We conducted a prospective, randomized interventional
study on 40 eyes in 39 patients with encapsulated blebs
developed within five months or less after primary
trabeculectomy with MMC and IOP $ 20 mmHg at the
Hospital das Clı´nicas of the University of Sa˜o Paulo, Brazil.
Data were collected from May 2010 to June 2011. None of
the eyes examined in this study received ocular hypotensive
agents after the first surgery. An encapsulated bleb was
defined as a localized, dome-shaped bleb surrounded by a
fibrous tissue called the ‘‘ring of steel’’ (figure 1). Patients
were randomized in two groups: TNR with 5-FU and MT.
Only one surgeon (RS) performed TNRs. A maximum of
two TNRs were allowed.
The study protocol was approved by the Ethics Committee
of the Hospital das Clı´nicas of the University of Sa˜o Paulo,
Brazil. After written informed consent was given and signed,
the TNR was performed. Topical anesthetic (tetracaine 0.5%),
antibiotic (Ofloxacin 2%) and 5% povidone-iodine solutions
were instilled into the eye. A lid speculum was inserted. At
the slit lamp, a 27-gauge needle attached to a 1-ml syringe
was passed into the subconjunctival space on the opposite
site of the scleral flap (figure 2). After that, 0.1 ml of 2%
lidocaine with epinephrine was injected. The needle was
advanced into a long track towards the cyst to minimize the
chance of leakage. Using up-and-down and back-and-forth
sweeping movements, the scar tissue was ruptured under-
neath the conjunctiva, always taking care not to perforate the
bleb wall. Then, aqueous flow was reestablished, increasing
the bleb size. The needle was removed, and, with a 25-gauge
needle attached to an insulin syringe, 5 mg (0.2 ml of 25 mg/
ml solution) of 5-FU was subconjunctivally injected superior
to the bleb (figure 2).
A topical antibiotic (ofloxacin 2%) was given four times a
day for two weeks, and a steroid (prednisolone 1%) was
given four times a day and was tapered as clinically
indicated.
The intraocular pressure was measured immediately after;
one day after; and one, three, six, and twelve months after the
procedure. Only the twelve-month IOP was analyzed in this
study. All patients were evaluated at the same time (10 am¡
one hour) to minimize fluctuation issues.
According to Shin et al. (16), the target intraocular
pressure was set for each patient based on the disease
progression severity and clinical history. Success was
considered as achieving the target pressure, # 18 mmHg,
and a 20% reduction from baseline at last follow-up
(without any hypotensive agents in the TNR group). The
exclusion criterion was the requirement of any further
treatments, including medical or surgical procedures. In the
MT group, topical hypotensive treatment was initialized
with a nonspecific beta-blocker and/or prostaglandin,
followed by carbonic anhydrase inhibitors and/or selective
alpha agonists, as necessary. Systemic medication was not
used. The exclusion criterion was the requirement of any
further surgical procedures.
The demographic data and characteristics of the study
population were collected.
Statistical analyses between variables were performed
using the Student’s t-test for parametric data and chi-square
and Mann-Whitney U tests for non-parametric data. Two
tailed p values ,0.05 were taken to indicate significance.
The SPSS software version 15.0 (SPSS Inc., Chicago, IL) was
used for statistical analyses.
& RESULTS
Among the 40 eyes analyzed during a 12-month time
period, 20 were randomized to TNR, and 20 were
randomized to MT. In the TNR group, the mean age was
57.30¡15.21 years (range 27-83 years). Fifty-five percent of
the subjects were female, and 65% were white. In the MT
group, the mean age was 63.30¡12.01 years (range 27-79
years), 60% were female, and 30% were white (Table 1). The
types of glaucoma are also shown in Table 1.
The mean times between the filtering surgery and initial
treatment after randomization were 43.15¡28.71 days
Figure 1 - Encapsulated bleb – localized, dome-shaped bleb
(arrows).
Figure 2 - A) Encapsulated bleb. B) Needle insertion site. C)
Subconjunctival 5-FU injection site.
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(range 17-153 days) in the TNR group and 51.60¡30.61 days
(range 23-139 days) in the MT group (p= 0.34).
The mean IOPs before the initial treatment were
25.15¡5.25 mmHg in the TNR group and 25.10¡4.36 mmHg
in the MT group (p= 0.58). The mean IOPs at the 12 month
follow-up were 12.14¡2.80 mmHg in the TNR group and
15.13¡2.07 mmHg in the MT group (p = 0.004) (Table 2).
Fourteen eyes (70%) in the TNR group and 15 eyes (75%) in the
MT group were considered successes (p= 0.89). Six eyes (30%)
were excluded in the TNR group (five required MT and one
further surgery), and five eyes (25%) were excluded in the MT
group (four required further filtering surgery and one was
submitted to the needling procedure) (p= 0.79).
The comparison of the IOP distribution before and after
the treatment in both groups is shown in Figure 3 (boxplot).
The mean number of needling procedures in the TNR
group was 1.35¡0.49, and the mean number of medications
in the MT group was 2.15¡0.74 at the last follow-up.
Complications after the needling procedure were
observed in three eyes (15%). One eye had a flat anterior
chamber and hyphema, and one eye had a small choroidal
effusion. Both were resolved with conservative treatment.
One eye had a flat anterior chamber and a choroidal
effusion that required surgical treatment.
& DISCUSSION
Several studies have demonstrated the efficacy of need-
ling revision in failing filtering blebs after filtration surgery
(1-4,6,12,13,16-21). However, as bleb morphology, time of
needling, follow-up period and successful criteria are
different in each study, comparisons of these studies would
not be meaningful.
Multiple bleb morphologies have been present in the
majority of studies; encapsulated blebs appear to have better
results in comparison to flat blebs (22). Rotchford & King
(12) suggested that high blebs were more likely to survive
than flat blebs if needling was performed within three
months after trabeculectomy. Iwach et al. (20) reported a
lower failure rate after the needling procedure in encapsu-
lated blebs (19%) in comparison to diffuse blebs (53%).
Interestingly, Broadway et al. (1) reported success rates of
47% for encapsulated blebs and 55% for flat blebs when
considering an IOP reduction to less than 22 mmHg as
success. To minimize the influence of bleb morphology, we
have only considered encapsulated blebs in this study.
The success rate of MT in eyes with encapsulated blebs
has been reported to range from 71 to 100% (23-25).
Comparisons between MT and surgical revision have been
previously reported. Costa et al. (13) compared eyes with
encapsulated blebs that were randomized to MT or the
needling procedure; at the last follow-up, they reported a
mean IOP of 16.09¡6.92 mmHg in the eyes receiving MT in
comparison to a mean IOP of 18.92¡6.39 mmHg in the eyes
submitted to the needling procedure in addition to MT. In
our study, we reported significantly better results after
TNR alone (without medication) in comparison to MT
(12.14¡2.80 mmHg and 15.13¡2.07 mmHg, respectively).
The use of adjunctive 5-FU may explain our better results in
eyes submitted to TNR. Several studies have shown that the
use of adjunctive antifibrotic agents seems to increase the
success rates of both MMC and 5-FU (1,3,17,20,26).
Although the time between the trabeculectomy and the
needling procedure does not seem to be a determinant of
success, (1) Rotchford & King (12) reported better results
when performing needling revisions within a three-month
period after trabeculectomy in elevated blebs. We also
performed revisions in elevated blebs (encapsulated) a short
period of time after trabeculectomy (51.60¡30.61 days).
Complications of the needling procedure after trabecu-
lectomy have been previously reported, but most were
considered minor and were resolved spontaneously (18,27).
Temporary conjunctival leakage, small hyphemas and
temporary shallowing of the anterior chamber have been
Table 1 - Demographic data and characteristics of the study population.
Transconjunctival needling revision (TNR) Medical treatment (MT) p value
Age (mean ¡ SD – range) 57.30¡15.21 (27-83) 63.30¡12.01 (27-79) 0.17
Gender
Female 11 (55%) 12 (60%)
Male 9 (45%) 8 (40%) 0.75
Race
White 13 (65%) 6 (30%)
Black 7 (35%) 13 (65%)
Asian 1 (5%) 0.07
Glaucoma Type
Primary open angle 17 (85%) 18 (90%)
Congenital 1 (5%) 1 (5%)
Inflammatory 1 (5%) -
Pseudoexfoliative - 1 (5%)
Neovascular 1 (5%) 0.55
Time from last surgery
to treatment (days) – range
43.15¡28.71 (17-153) 51.60¡30.61 (23-139) 0.34
Table 2 - Average intraocular pressure before and after randomization (at the 12-month follow-up) in the TNR and MT
groups.
Transcojunctival needling revision (TNR) Medical Treatment (MT) P value
IOP pre-treatment (mmHg) 25.15 ¡ 5.25 25.10 ¡ 4.36 0.58
IOP post-treatment at 12-months follow
up (mmHg)
12.14 ¡ 2.80 15.13 ¡ 2.07 0.004
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reported (18,27). However, some reports have suggested
more severe complications when performing needling in
flat and scarred blebs (28,29). In our study, we observed
complications in three eyes (15%); only one eye required
further surgical treatment.
In this study, we achieved similar success rates in eyes
randomized to MT in comparison to TNR with 5-FU (75%
versus 70%, respectively). However, a significantly lower
mean IOP after TNR was observed. By including only
encapsulated blebs in this study, the accuracy of measuring
successful treatment was increased through the elimination
of variations in morphological characteristics. We suggest
that TNR with adjunctive 5-FU without further medical
therapy is very effective at maintaining a successful IOP for
12 months. The limitations of this prospective study include
the small sample size and the short follow-up period.
In conclusion, over a 12-month follow-up, this study
showed that TNR with adjunctive 5-FU is as effective as MT.
However, TNR has the advantage of being compliance-free
and of recovering previously failed trabeculectomies in eyes
with encapsulated blebs.
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Figure 3 - Boxplot showing a comparison of IOP profiles before
and after randomization at the 12-month follow-up.
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